A detailed history of Quantinno Capital Management LP transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Quantinno Capital Management LP holds 7,537 shares of SUPN stock, worth $290,551. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,537
Previous 7,605 0.89%
Holding current value
$290,551
Previous $203,000 15.76%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$25.77 - $35.16 $1,752 - $2,390
-68 Reduced 0.89%
7,537 $235,000
Q2 2024

Aug 14, 2024

BUY
$25.99 - $33.85 $21,701 - $28,264
835 Added 12.33%
7,605 $203,000
Q1 2024

May 14, 2024

BUY
$27.11 - $35.17 $183,534 - $238,100
6,770 New
6,770 $230,000
Q4 2022

Feb 13, 2023

SELL
$31.09 - $37.88 $435 - $530
-14 Reduced 0.22%
6,305 $224,000
Q3 2022

Nov 07, 2022

BUY
$28.79 - $35.41 $181,924 - $223,755
6,319 New
6,319 $214,000
Q4 2021

Feb 14, 2022

SELL
$26.37 - $34.22 $268,657 - $348,633
-10,188 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$24.15 - $31.45 $244,373 - $318,242
-10,119 Reduced 49.83%
10,188 $267,000
Q4 2020

Feb 09, 2021

SELL
$17.7 - $25.81 $119,156 - $173,752
-6,732 Reduced 24.9%
20,307 $511,000
Q3 2020

Nov 16, 2020

BUY
$20.2 - $25.05 $546,187 - $677,326
27,039 New
27,039 $563,000
Q2 2020

Aug 14, 2020

SELL
$17.09 - $24.89 $609,480 - $887,652
-35,663 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$14.45 - $24.69 $515,330 - $880,519
35,663 New
35,663 $642,000
Q4 2019

Feb 14, 2020

SELL
$19.93 - $29.13 $288,626 - $421,860
-14,482 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$25.47 - $33.37 $368,856 - $483,264
14,482 New
14,482 $398,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $2.06B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Quantinno Capital Management LP Portfolio

Follow Quantinno Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantinno Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantinno Capital Management LP with notifications on news.